Incyte Corporation
INCYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. With a market capitalization of $23.45B, it sits in large-cap territory. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Market Cap
$23.45B
Beta
0.74
P/E (TTM)
14.89
P/E (Fwd)
13.33
EPS (TTM)
$7.77
EPS (Fwd)
$8.68
ROE
30.7%
ROA
16.8%
Cash
$4.54B
Total Debt
$38.3M
Free CF
$1.18B
52W Change
26.8%
Annual Financials
Cash vs Debt
Where INCY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INCY finished 3.34% above its 150-day moving average ($109.59) and 5.28% above its 200-day moving average ($107.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INCY overbought or oversold?
At the October 20, 2026 close, INCY's RSI(14) was 26.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $4.54B in cash comfortably exceeding the $38.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $1.18B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 30.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 16.8% further supports the picture of efficient asset utilization. Revenue has grown from $3.39B (2022) to $5.14B (2025), reflecting a 51% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Incyte Corporation and its sector.